甘李药业(603087) - 2023 Q3 - 季度财报

Financial Performance - In Q3 2023, the company's revenue reached ¥675,905,764.02, representing a 68.10% increase compared to the same period last year[4] - The net profit attributable to shareholders was ¥132,320,637.97, with a year-to-date net profit of ¥266,475,880.66[4] - The basic earnings per share for Q3 2023 was ¥0.24, while the diluted earnings per share was also ¥0.24[4] - The company achieved a total revenue of ¥1,905,670,877.67 for the year-to-date period, marking a 54.07% increase compared to the same period last year[4] - Net profit for the third quarter of 2023 was ¥266,475,847.45, compared to a net loss of ¥413,805,945.37 in the third quarter of 2022, marking a turnaround in profitability[15] - Basic and diluted earnings per share for the third quarter of 2023 were both ¥0.47, recovering from a loss of ¥0.74 per share in the same quarter of 2022[16] Sales Performance - Domestic sales revenue for the first three quarters of 2023 was ¥1,629,403,700.00, a 55.18% increase from the same period in 2022[9] - International sales revenue increased by 237.47% year-on-year, reaching ¥176,092,400.00[9] - The sales volume of domestic insulin products grew by 70.06% year-on-year, significantly contributing to revenue growth[9] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥10,825,037,574.61, reflecting a 2.06% increase from the end of the previous year[4] - Total assets as of September 30, 2023, are ¥10,825,037,574.61, compared to ¥10,606,912,380.06 at the end of 2022, reflecting a growth of approximately 2.1%[14] - Total liabilities decreased to ¥934,593,898.55 from ¥1,021,272,746.19, a reduction of about 8.5%[14] - Total equity attributable to shareholders increased to ¥9,890,606,224.90 from ¥9,585,802,149.50, representing an increase of approximately 3.2%[14] Cash Flow - The company reported a net cash flow from operating activities of -¥76,956,258.80 for the year-to-date period, a decrease of 116.70% compared to the previous year[4] - The company reported a net cash outflow from operating activities of ¥76,956,258.80 for the first three quarters of 2023, a decline from a net inflow of ¥460,796,007.58 in the same period of 2022[17] - Cash and cash equivalents as of September 30, 2023, amount to ¥2,093,406,319.02, a decrease from ¥2,890,266,792.18 at the end of 2022, representing a decline of approximately 27.6%[13] - Cash and cash equivalents at the end of the third quarter of 2023 stood at ¥393,508,471.53, compared to ¥329,231,010.13 at the end of the same period in 2022[17] - The company experienced a significant increase in cash inflow from investment activities, totaling ¥5,914,666,921.80 in 2023 compared to ¥3,631,192,274.78 in 2022[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 79,170[10] - The largest shareholder, Gan Zhongru, holds 31.32% of the shares, with the top ten shareholders collectively holding a significant portion of the company's equity[10] - The company has no reported related party transactions or concerted actions among shareholders[11] Research and Development - Research and development expenses for the first three quarters of 2023 amounted to ¥369,945,734.16, slightly down from ¥393,203,255.33 in the same period of 2022[15] Inventory and Receivables - Trade receivables increased to ¥398,288,006.98 from ¥176,251,160.43, showing a growth of approximately 126.9% year-over-year[13] - Inventory as of September 30, 2023, is ¥858,848,392.87, up from ¥648,645,609.14, indicating an increase of about 32.3%[13]